Guardant Health 3Q 2026: Revenue $360.98M, EPS ($0.93) — 10-Q Summary

Guardant Health’s third-quarter revenue increased 36% year over year, while its net loss widened. Growth was driven by higher oncology and Shield screening test volumes; increased research, commercial infrastructure, marketing and legal costs contributed to the larger loss.Financial Highlights¹ Rep…